Literature DB >> 29154212

Consensus scoring model for the molecular docking study of mTOR kinase inhibitor.

Dong-Dong Li1, Xiang-Feng Meng2, Qiang Wang2, Pan Yu2, Lin-Guo Zhao2, Zheng-Ping Zhang3, Zhen-Zhong Wang4, Wei Xiao5.   

Abstract

The discovery of mammalian target of rapamycin (mTOR) kinase inhibitors has always been a research hotspot of antitumor drugs. Consensus scoring used in the docking study of mTOR kinase inhibitors usually improves hit rate of virtual screening. Herein, we attempt to build a series of consensus scoring models based on a set of the common scoring functions. In this paper, twenty-five kinds of mTOR inhibitors (16 clinical candidate compounds and 9 promising preclinical compounds) are carefully collected, and selected for the molecular docking study used by the Glide docking programs within the standard precise (SP) mode. The predicted poses of these ligands are saved, and revaluated by twenty-six available scoring functions, respectively. Subsequently, consensus scoring models are trained based on the obtained rescoring results by the partial least squares (PLS) method, and validated by Leave-one-out (LOO) method. In addition, three kinds of ligand efficiency indices (BEI, SEI, and LLE) instead of pIC50 as the activity could greatly improve the statistical quality of build models. Two best calculated models 10 and 22 using the same BEI indice have following statistical parameters, respectively: for model 10, training set R2=0.767, Q2=0.647, RMSE=0.024, and for test set R2=0.932, RMSE=0.026; for model 22, raining set R2=0.790, Q2=0.627, RMSE=0.023, and for test set R2=0.955, RMSE=0.020. These two consensus scoring model would be used for the docking virtual screening of novel mTOR inhibitors.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antitumor activity; Consensus scoring models; Ligand efficiency indices; Molecular docking; mTOR kinase inhibitors

Mesh:

Substances:

Year:  2017        PMID: 29154212     DOI: 10.1016/j.jmgm.2017.11.003

Source DB:  PubMed          Journal:  J Mol Graph Model        ISSN: 1093-3263            Impact factor:   2.518


  7 in total

Review 1.  Empirical Scoring Functions for Structure-Based Virtual Screening: Applications, Critical Aspects, and Challenges.

Authors:  Isabella A Guedes; Felipe S S Pereira; Laurent E Dardenne
Journal:  Front Pharmacol       Date:  2018-09-24       Impact factor: 5.810

2.  Anticancer compound XL765 as PI3K/mTOR dual inhibitor: A structural insight into the inhibitory mechanism using computational approaches.

Authors:  Mohd Rehan
Journal:  PLoS One       Date:  2019-06-27       Impact factor: 3.240

Review 3.  In Silico Strategies in Tuberculosis Drug Discovery.

Authors:  Stephani Joy Y Macalino; Junie B Billones; Voltaire G Organo; Maria Constancia O Carrillo
Journal:  Molecules       Date:  2020-02-04       Impact factor: 4.411

4.  Construction of Quantitative Structure Activity Relationship (QSAR) Models to Predict Potency of Structurally Diversed Janus Kinase 2 Inhibitors.

Authors:  Saw Simeon; Nathjanan Jongkon
Journal:  Molecules       Date:  2019-12-01       Impact factor: 4.411

5.  Physicochemical and Biological Evaluation of Curdlan-Poly(Lactic-Co-Glycolic Acid) Nanoparticles as a Host-Directed Therapy Against Mycobacterium Tuberculosis.

Authors:  S D'Souza; S M Du Plessis; S Egieyeh; R B Bekale; R E Maphasa; A F Irabin; S L Sampson; A Dube
Journal:  J Pharm Sci       Date:  2021-09-14       Impact factor: 3.534

Review 6.  Key Topics in Molecular Docking for Drug Design.

Authors:  Pedro H M Torres; Ana C R Sodero; Paula Jofily; Floriano P Silva-Jr
Journal:  Int J Mol Sci       Date:  2019-09-15       Impact factor: 5.923

Review 7.  Application of Various Molecular Modelling Methods in the Study of Estrogens and Xenoestrogens.

Authors:  Anna Helena Mazurek; Łukasz Szeleszczuk; Thomas Simonson; Dariusz Maciej Pisklak
Journal:  Int J Mol Sci       Date:  2020-09-03       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.